You'll notice in the company's most recent guidance they expect the trial to end sometime in H1 of 2019. Therefore it's been pushed back considerably. 

Based on our crude model, we would expect the 250th event to occur sometime in March with the potential to stretch into April. 

This is based off either assuming EXAMINE's patient population as placebo which gives a RRR of 43%. Or if you assume the patient population has 10% lower MACE rates you still get a RRR of 30% and a similar range of dates. I would expect the company to find financing here to pay loan back.

Note these estimates are based off the 200th MACE happening just prior to the September 12th conference call.